Objective. To compare the probability of cancer in a solitary pulmonary nodule using standard criteria with Bayesian analysis and result of 2-[F-18] fluoro-2-deoxy-D-glucose-positron emission tomographic (FDG-PET) scan. Setting. A university hospital and a teaching Veteran Affairs
Medicine is a science of uncertainty and an art of probability from published data would require a very large study
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group, and this has not been done. However, in the study by Swensen et al 6 an internal validation was Management of the solitary pulmonary nodule (SPN) achieved by developing the probability model with is often challenging. 1 Since SPNs are not typically asmultivariate logistic regression in a large cohort (n= sociated with symptoms, most are incidental discoveries.
419) and testing it on a separate cohort (n=210). The As the overall prevalence of malignancy in SPNs is high correlation was excellent. at 20-40%, the primary goal of management is to identify and resect malignant nodules promptly. An important secondary goal is to avoid resecting benign nodules. The standard dictum since the 1950s has been Positron emission tomography (PET): first to resect all nodules promptly unless their benign nature introductory article could be established conclusively, assuming the subject The first introductory article by Dewan et al reports a is suitable for surgery in other respects. The accepted retrospective evaluation of the diagnostic role of PET criteria for benignity included: (a) the presence of certain in 52 subjects with SPNs. 7 In these subjects PET was patterns of intranodular calcification, and/or (b) stability 95% sensitive, 87% specific, and 92% accurate for (no growth of the nodule for a period of two years or detecting cancer. Other investigators have reported simlonger). More recently there has been a search for ilar results for PET test performance, although large approaches which will decrease the incidence of unprospective studies have not yet been performed. [8] [9] [10] necessary surgical resection of benign nodules and deThe corresponding likelihood ratios for malignancy were crease the overall cost of management.
7.11 for a positive PET result and 0.06 for a negative PET study. Thus, the positive predictive value and negative predictive value of PET were both high. The likelihood ratio of 7.11 for a positive PET study was Estimating the probability of malignancy It has long been accepted that an accurate estimation greater than the likelihood ratios for each one of the "conventional" predictor variables employed by Cumof the probability that an SPN is malignant would provide significant assistance in management decisions. 1 mings et al, 4 and all but one (cavity wall thickness) of the characteristics identified by Gurney et al. 5 Clinicians often attempt to estimate such probabilities intuitively, but a number of biases may confound this Using a baseline prevalence of malignancy in SPNs of 40%, Dewan et al calculated that a likelihood ratio process.
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Several groups of investigators have developed formal of 7.11 for a positive PET indicated a pCA of 82.4%, and a likelihood ratio of 0.06 for a negative PET indicated a guidelines for estimating the probability of cancer (pCA) in SPNs. [3] [4] [5] [6] Predictions are based on patient charpCA of 3.8%. When they compared these probability estimates with those obtained using the standard clinical acteristics and the results of non-invasive imaging studies, particularly computed tomographic (CT) scanning.
and CT criteria, they found that the PET based estimates were more accurate for predicting (or excluding) These "predictor variables" include important patient characteristics such as "baseline" prevalence of maligcancer in individual subjects. This is not surprising since clinical and CT criteria are not generally considered to nancy in solitary nodules in the population under consideration, age, smoking status, and a prior history be particularly sensitive or specific. More surprising was their finding that the PET based of extrapulmonary malignancy. Imaging criteria may include nodule location, diameter size, edge characterprobability estimates were more accurate than estimates obtained by combining the PET results with the standistics, growth rate, calcification pattern on the CT scan, and cavity wall thickness if cavitation is present.
ard clinical and CT criteria. In other words, the addition of clinical and CT characteristics to the calculation had Likelihood ratios for each of the clinical or radiographic characteristics chosen may be combined using a negative impact on diagnostic accuracy-that is, one would do better to ignore the standard criteria and base Bayes' theorem to update the probability of malignancy derived from the baseline prevalence. After calculating strategies for subsequent management solely on the results of PET. the pCA, decisions to take biopsy specimens, perform further imaging studies, carry out a diagnostic/theraThis seemingly counter-intuitive result is not easily explained. It seems that some of the likelihood ratios peutic thoracotomy, or manage the patient expectantly can be taken accordingly, as will be discussed later. The underlying the standard criteria are not readily applied generally, at least with respect to this particular study revised probability estimate cannot differentiate between malignancy or benignity with certainty, but rather serves sample. The 52 subjects studied by Dewan et al almost certainly differed from the populations used to develop as a guide to subsequent decision making.
The validity of the use of likelihood ratios in Bayesian the likelihood ratios with respect to both observed and unobserved characteristics. One notable observed probability assessment depends upon certain assumptions that may or may not be valid. The two major difference was the extremely high overall prevalence of malignancy (71%) in the population studied by Dewan ones are that the predictor variables are conditionally independent and that the baseline prevalence of maliget al. Since the prevalence of malignant SPNs was much lower in most of the studies used to develop nancy employed in the calculations is appropriate for the population being studied. External validation of the likelihood ratios for the standard criteria, it is not surprising that the latter would underestimate the pCA probability calculations with likelihood ratios derived group.bmj.com on June 21, 2017 -Published by http://thorax.bmj.com/ Downloaded from in many of the cases studied by Dewan. This problem in natural units such as life years saved or cases of pneumonia prevented. Analysis of cost effectiveness in generalising is not unique to this example. Whenever clinical trial results are used to support decision making always compares two or more interventions and incremental cost effectiveness ratios are calculated by in individual patients or other groups of patients, the applicability of the findings of the trial (external validity) dividing the difference in costs by the difference in health effects between competing interventions. A special type must be considered.
It is axiomatic that spectrum bias in the initial studies of cost effectiveness analysis measures health effects in terms of both quality and duration of life. Such an of a new test will give somewhat inflated values for sensitivity and specificity. Nevertheless, it seems very approach is sometimes called a cost utility analysis. The "quality adjusted life year" (QALY) is the preferred likely that PET will prove to be very useful in the diagnosis and management of SPN and may eventually denominator for this type of analysis, although even this measure is less than perfect. 13 14 However, using QALYs replace needle aspiration biopsy in many situations. If the results of these preliminary studies are confirmed, as the measure of effectiveness produces the most generalisable results so that different health care inthe negative predictive value of PET will be high and expectant (non-surgical) management in many or most terventions can be compared both within and across different diseases. For example, in acute myocardial patients who have a negative PET will be a reasonable choice. If PET imaging substantially reduces the number infarction, if the incremental cost effectiveness of tissue plasminogen activator compared with streptokinase is of unnecessary surgical resections of benign nodules, it will also probably prove to be highly cost effective. A $30 300 per additional QALY saved, this value should be judged in the context of the calculated cost effectlarge multicentre Veterans Administration Cooperative Study is currently underway to define better PET periveness of other commonly accepted health care interventions that serve as benchmarks. Occasionally, cost formance and cost effectiveness for SPN diagnosis and for tumour staging.
effectiveness studies report average cost effectiveness ratios in which the costs of a single intervention are Furthermore, the high sensitivity of PET scanning may encourage local but potentially curative resection divided by its health effects. Average cost effectiveness ratios are difficult to interpret and potentially misleading of SPNs using video assisted thoracoscopy whenever thoracotomy and lobectomy are considered insince they do not reveal the incremental benefits and costs of adopting an intervention compared with some appropriate because of co-existing morbidity.
alternative. Many other considerations arise when interpreting the results of cost effectiveness studies: was the analysis       Prior to the availability of PET, three formal decision performed from a societal perspective or some other perspective; how did the authors determine costs; how analysis studies were published on the effectiveness of various strategies for SPN management. 3 11 12 While the far into the future were costs tallied; how were costs and health effects discounted? Answers to these quesdesign of the decision trees and the choice of probability variables differed somewhat, the conclusions were simtions may have a major impact on the validity and general applicability of the results of such studies. ilar. The average utility (expected value) of each strategy was quantified in terms of average years of expected When an intervention or strategy is found to be less expensive and more effective in a cost effectiveness survival. The level of pCA had the greatest influence on expected utility. study it is often called a dominant alternative. If the study results are valid and applicable to the reader's As might be expected, the strategy of immediate thoracotomy was optimal when the pCA was relatively setting, the strategy should be adopted. More commonly, the more effective strategy is also more expensive. high. The strategy of watchful waiting, which included prospective monitoring with serial chest radiographs
In such cases it is not obvious whether the improvements in health justify the increased costs. Thus, cost effectfollowed by prompt resection if growth occurred, was equal or preferable to other strategies by a small margin iveness studies may serve to inform decision making about competing health care interventions but do not when pCA was low, usually <10%. The study by Cummings et al included a mechanism for quantifying the obviate the need for value judgments in many instances. "hazard of delay" inherent in such watchful waiting strategies. 11 Over relatively wide intermediate ranges of values for pCA, the strategy of needle aspiration biopsy Cost effectiveness in lung cancer staging and diagnosis: second introductory article had a marginally greater utility than immediate thoracotomy and a more obvious advantage over the watchful In 1988 Black and associates published a well designed cost effectiveness study on a special subset of SPNs-the waiting strategy.
It has long been recognised that factors other than T1N0M0 pulmonary nodule-concentrating on the value of routine mediastinal CT studies. 15 As many of the duration of life should be considered in quantifying the effectiveness of a strategy. For example, five years the assumptions employed may no longer be valid, their conclusion that CT scanning is cost effective may need of life in chronic pain or disability is less desirable than five years of survival without symptoms. Adjustments to be re-examined and revised. The value of sputum cytological studies, a traditional technique for lung canfor long term reductions in the quality of life were not employed in the above-mentioned studies, nor were cer diagnosis, has recently become a further focus of attention. Two groups of researchers have reached opthere any formal considerations of cost. Quality of life adjustments will typically reduce calculated effectiveness posite conclusions about the cost effectiveness of this diagnostic test. in strategies (such as thoracotomy) that produce chronic complications in some instances.
In the second introductory article Goldberg-Kahn et al 16 reported decision analysis to compare the cost in the USA per correct diagnosis for various combinations of sputum cytology, fine needle aspiration biopsy, bron-       choscopy, and open biopsy. In their baseline analysis they concluded that proceeding directly to open biopsy In cost effectiveness analysis health effects are measured group.bmj.com on June 21, 2017 -Published by http://thorax.bmj.com/ Downloaded from (thoracotomy) resulted in the lowest average cost effectpheral lesions sputum cytology was also found to be valuable, despite the fact that it was assumed to have a iveness ($12 888 per correct diagnosis). Conversely, a strategy which included sputum cytology as the initial sensitivity of only 20% for these lesions compared with 40% for central lesions. Life expectancy was found to test (followed by bronchoscopy, needle biopsy and/or open biopsy) resulted in the highest cost ($63 424) per be similar for sputum based and non-sputum based strategies. The least expensive strategy (needle biopsy, correct diagnosis.
This result seems counter-intuitive, especially since followed by bronchoscopy, followed by expectant management) did not include sputum cytology. However, the total cost for all four procedures was only $14 090. However, if the number of correct diagnoses was much the incremental cost effectiveness of adding sputum cytology to this approach was $27 600 per additional lower for strategies involving initial sputum cytology than for open biopsy as the initial test, then the cost life year saved, which is roughly comparable to the cost effectiveness of other widely accepted health care per correct diagnosis for initial sputum cytology could conceivably be much higher than the total cost of all interventions. 18 The results of this analysis varied according to the four procedures. The authors did not report the number of correct and incorrect diagnoses for each strategy, but prevalence of malignant disease as demonstrated by sensitivity analysis. For central lesions sputum cytology the large difference in cost per correct diagnosis could only be explained if the percentage of incorrect diagnoses was clearly not cost effective when the pCA was less than or equal to 0.10, and probably not cost effective obtained with the initial sputum cytology strategy was very large. This may have been so, but it is disingenuous when the pCA was as high as 0.20. Thus, bronchoscopy followed by needle biopsy followed by expectant manto argue that the investigatory strategy was a failure because the initial use of sputum cytology gave falsely agement was the preferred strategy when the pCA was very low. For peripheral lesions the sputum first strategy negative results when subsequent tests within the strategy were positive.These considerations aside, two funresulted in an incremental cost effectiveness ratio of $69 856 per life year saved when the pCA was 0.30 and damental problems limit the validity and applicability of the results of this analysis. Firstly, and most important, $463 270 per life year saved when the pCA was 0.10 when compared with a representative non-sputum based the authors reported average cost effectiveness ratios rather than incremental cost effectiveness ratios. As strategy. If an incremental cost effectiveness ratio of $30 000-50 000/life year saved is adopted as a reasonpreviously mentioned, this produces results that are difficult to interpret and potentially misleading. Secable threshold, then sputum based strategies are only cost effective when the pCA for a peripheral nodule is ondly, it is not clear how to interpret cost per correct diagnosis as a measure of cost effectiveness since no greater than 0.40.Their decision model assumes that bronchoscopic biopsy and needle biopsy are conreasonable benchmarks exist for comparison.
A decision analytical approach to evaluate the cost ditionally independent, which is almost certainly incorrect, but this probably does not invalidate the and effectiveness of strategies that included sputum cytology compared with those that did not was also conclusions reached. Unfortunately, neither of these cost effectiveness studused by Raab et al. 17 These authors expressed their results in terms of incremental costs and life exies included PET as a possible diagnostic test. If PET is ultimately confirmed to be highly accurate for the pectancies, so their results are more easily interpreted and generalised. Like Goldberg-Kahn et al, they evaludiagnosis of pulmonary nodules and mass lesions, the cost effectiveness of sputum cytology will need to be ated various combinations of sputum cytology, fine needle aspiration biopsy, bronchoscopy, and open bireassessed and compared with PET based strategies. In the future the use of standard clinical and CT criteria opsy (via thoracoscopy). In addition, they included the possibility of expectant management for those with nonto estimate the pCA may still be helpful in choosing the optimal strategy, although clinicians must continue diagnostic results on bronchoscopy and needle biopsy (with or without non-diagnostic initial sputum cytoto exercise caution when generalising the results of prediction rules and decision models to decision making logy). Furthermore, this group considered central and peripheral lesions separately, and assumed that the test at the individual patient level. performance for sputum cytology, bronchoscopy, and needle biopsy varied depending on whether a lung lesion was central or peripheral in location. Another advantage        While much recent interest has focused on PET for of this model is that the authors incorporated estimates of morbidity and mortality for each of the diagnostic SPN diagnosis, equal attention has been given to PET as a modality for mediastinal staging in non-small cell procedures.
They found that, for central lung lesions, calculated lung cancer. Preliminary studies suggest that PET is 80-90% sensitive and specific for identifying malignant life expectancies were similar for strategies that used initial sputum cytology and those strategies in which mediastinal lymph nodes. [19] [20] [21] CT scanning, in comparison, is notoriously inaccurate for mediastinal sputum cytology was not employed. One exception was that performing sputum cytology prior to open biopsy staging. 22 23 Gambhir and associates recently reported a cost via thoracoscopy increased life expectancy by an average of 107 days compared with using open biopsy as the effectiveness evaluation of PET for mediastinal staging. 24 Using decision modelling this group compared initial test. With respect to costs, sputum cytology as the initial test was always less expensive than a comparable costs and outcomes for PET based strategies with standard strategies that did not include PET. The standard strategy without initial sputum cytology. Thus, in contrast to the findings of Goldberg-Kahn et al, strategies strategy consisted of CT scanning followed by mediastinal biopsy when CT was positive, and thoracotomy which included sputum cytology almost always increased life expectancy and always resulted in lower when CT was negative. PET was incorporated into the diagnostic plan in one of two possible ways. In the costs. The optimal diagnostic strategy consisted of sputum cytology followed by bronchoscopy and then needle conservative PET strategy the authors assumed that mediastinal biopsy would be performed following a biopsy, as necessary, with subsequent expectant management if all three tests were non-diagnostic. For peripositive PET, regardless of CT results, or following a group.bmj.com on June 21, 2017 -Published by http://thorax.bmj.com/ Downloaded from positive result on CT if PET was negative. In the less surgery. For a cost effectiveness analysis based on a societal perspective costs for subsequent care should be conservative PET strategy, biopsy specimens were taken only when PET and CT results were discordant. Thus, included, in addition to costs for diagnostic testing and initial surgical treatment. In this analysis no costs are in this strategy concordant positive results were assumed to be correct. For the base case analysis the sensitivity assigned for non-surgical treatment in those thought to have unresectable disease. Thus, the 1.7% of patients and specificity for CT scanning were assumed to be 67% and 73% and the corresponding values for PET with false positive staging evaluations in the less conservative PET strategy incur no costs beyond those for were assumed to be 90% and 91%.
The authors calculated that the conservative PET CT scanning and PET. On a more technical but related note, the authors estimated costs using billed charges strategy was less costly than the standard strategy, with an estimated cost saving of $1154 per patient. Furas a surrogate. While their cost estimates appear reasonable, charges and costs often differ widely. thermore, they reported that average life expectancy increased by almost three days using the conservative Other modelling assumptions might also be challenged. These authors assumed that CT and PET results PET strategy. Thus, compared with the standard strategy, the conservative PET strategy was dominant. The were independent. In fact, preliminary studies suggest that the test performance of PET depends partly on the less conservative PET strategy was also calculated to be less costly than the standard approach, with an estimated results of CT scanning. More specifically, PET is most sensitive in the setting of a positive CT scan, and most cost savings of $2267 per patient. However, the less conservative PET strategy resulted in false positive staspecific when the CT scan is negative. 25 This potentially limits the usefulness of PET since ideally PET should ging evaluations in 1.7% of the patients. The authors did not report calculated differences in life expectancy be very specific following a positive CT scan if one wishes to minimise the number of false positive staging between the less conservative PET and standard strategies, but false positive evaluations would be expected evaluations that result in missed opportunities for surgical cure. Gambhir and colleagues also limit the range to result in missed opportunities for surgical cure and shortened survival.
of possible strategic alternatives. For selected patients with non-small cell lung cancer at very low risk for Several problems appear to limit the conclusions of this analysis. Firstly, the perspective of the analysis is mediastinal lymph node involvement it is conceivable that prompt surgery without diagnostic testing would not clearly specified although a hospital perspective is inferred. Secondly, the time horizon of the analysis may be the most cost effective strategy, but this option is not considered. Finally, the authors assumed that not be sufficiently long, depending on the selected perspective. The authors limited their time frame to the mediastinal biopsy was 100% accurate although the sensitivity of mediastinoscopy and other biopsy properiod of diagnostic evaluation and initial treatment and only included costs for CT scanning, PET, biopsy, and cedures is known to be less than perfect.
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LEARNING POINTS * The solitary pulmonary nodule (SPN), usually an asymptomatic incidental radiological finding, is one of the more common methods of presentation of bronchogenic carcinoma, currently the leading cause of death from cancer in both men and women. * If diagnosed and treated promptly, the malignant SPN will have a five year survival rate of 40-80%; the smaller the nodule at the time of resection, the higher the five year survival rate. * It is possible to calculate the probability that the nodule is malignant (pCA) by Bayesian means from clinical and radiological findings, thereby providing assistance in the choice of definitive investigative/therapeutic strategies. * Standard strategies include immediate thoracotomy, non-thoracotomy biopsy of the nodule (usually by transthoracic needle aspiration), and "watch and wait" with serial chest radiographs. * Growth of the nodule during the watch and wait period is an indication for prompt thoracotomy. * In a given patient the calculated value for pCA indicates which strategy is likely to be most effective in terms of life expectancy. * Positron emission tomography (PET) is a new imaging process which appears to have a high sensitivity and specificity in detecting malignancy in the SPN, the regional and mediastinal lymph nodes, and in distant organs but further studies, particularly cost effectiveness analyses, are needed to determine its exact role. * Despite criticisms and controversy over the value of sputum analyses, a recent study suggests that it is cost effective in certain circumstances, depending upon the pCA and whether the nodule has a central or peripheral location.
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